Fig. 4: TRIM11 promotes mammary tumorigenesis and regulates KDM5C in vivo.
From: Regulation of KDM5C stability and enhancer reprogramming in breast cancer
A Tumor growth of Trim11 wild type or KO MMTV-PyVT mice, indicated as total tumor volume / mouse number (Trim11+/+ mice, n = 12; Trim11+/− mice, n = 7). B, C The average weight and volume of breast tumors when sacrificed, shown as mean ± SEM (Trim11+/+ tumors, n = 46; Trim11+/− tumors, n = 24). D, E Representative Kdm5c immunohistochemical (IHC) staining of breast cancer tissues from Trim11+/+ and Trim11+/− MMTV-PyVT mice (n = 6). F Representative TRIM11 and KDM5C IHC staining in tumor tissue microarray (TMA). G, H Expression of TRIM11 and KDM5C in human breast cancer TMA was shown as mean, min to max and all points according to molecular subclasses. I Correlation of TRIM11 and KDM5C expression level in TMA. J Overall survival of BRCA patients with high and low TRIM11 expression was analyzed and plotted using GSE3494 datasets and the Kaplan–Meier method. Statistical analysis was performed using unpaired two-tailed Student’s t test (A, B, C, D, G, H), *p value ≤ 0.05, **p value ≤ 0.01, ***p value ≤ 0.001.
